Risk factors for serious prescription opioid-related toxicity or overdose among Veterans Health Administration patients B Zedler, L Xie, L Wang, A Joyce, C Vick, F Kariburyo, P Rajan, O Baser, ... Pain medicine 15 (11), 1911-1929, 2014 | 288 | 2014 |
Development of a risk index for serious prescription opioid-induced respiratory depression or overdose in Veterans' Health Administration patients B Zedler, L Xie, L Wang, A Joyce, C Vick, J Brigham, F Kariburyo, O Baser, ... Pain Medicine 16 (8), 1566-1579, 2015 | 155 | 2015 |
A medication adherence and persistence comparison of hypertensive patients treated with single-, double-and triple-pill combination therapy L Xie, F Frech-Tamas, E Marrett, O Baser Current Medical Research and Opinion 30 (12), 2415-2422, 2014 | 113 | 2014 |
Analysis of the relationship between psoriasis symptom severity and quality of life, work productivity, and activity impairment among patients with moderate-to-severe psoriasis … C Lewis-Beck, S Abouzaid, L Xie, O Baser, E Kim Patient preference and adherence, 199-205, 2013 | 95 | 2013 |
Sickle cell disease complications: Prevalence and resource utilization N Shah, M Bhor, L Xie, J Paulose, H Yuce PLoS One 14 (7), e0214355, 2019 | 94 | 2019 |
Prevalence of diagnosed opioid abuse and its economic burden in the veterans health administration O Baser, L Xie, J Mardekian, D Schaaf, L Wang, AV Joshi Pain Practice 14 (5), 437-445, 2014 | 88 | 2014 |
Real-world insulin treatment persistence among patients with type 2 diabetes W Wei, C Pan, L Xie, O Baser Endocrine Practice 20 (1), 52-61, 2014 | 76 | 2014 |
Healthcare utilization and costs of Veterans Health Administration patients with schizophrenia treated with paliperidone palmitate long-acting injection or oral atypical … O Baser, L Xie, J Pesa, M Durkin Journal of medical economics 18 (5), 357-365, 2015 | 68 | 2015 |
Comparison of real-world adherence, healthcare resource utilization and costs for newly initiated valsartan/amlodipine single-pill combination versus angiotensin receptor … O Baser, LM Andrews, L Wang, L Xie Journal of medical economics 14 (5), 576-583, 2011 | 67 | 2011 |
Treatment patterns and economic burden of sickle-cell disease patients prescribed hydroxyurea: a retrospective claims-based study N Shah, M Bhor, L Xie, R Halloway, S Arcona, J Paulose, H Yuce Health and Quality of Life Outcomes 17, 1-11, 2019 | 62 | 2019 |
Real-world outcomes of US employees with type 2 diabetes mellitus treated with insulin glargine or neutral protamine Hagedorn insulin: a comparative retrospective database study L Wang, W Wei, R Miao, L Xie, O Baser BMJ open 3 (4), e002348, 2013 | 57 | 2013 |
Does pen help? A real-world outcomes study of switching from vial to disposable pen among insulin glargine-treated patients with type 2 diabetes mellitus L Xie, S Zhou, W Wei, J Gill, C Pan, O Baser Diabetes technology & therapeutics 15 (3), 230-236, 2013 | 55 | 2013 |
Examining the effect of medication adherence on risk of subsequent fracture among women with a fragility fracture in the US medicare population A Keshishian, N Boytsov, R Burge, K Krohn, L Lombard, X Zhang, L Xie, ... Journal of Managed Care & Specialty Pharmacy 23 (11), 1178-1190, 2017 | 51 | 2017 |
Economic burden, mortality, and institutionalization in patients newly diagnosed with Alzheimer’s disease CM Black, H Fillit, L Xie, X Hu, MF Kariburyo, BM Ambegaonkar, O Baser, ... Journal of Alzheimer's Disease 61 (1), 185-193, 2018 | 48 | 2018 |
Outcomes and treatment patterns of adding a third agent to 2 OADs in patients with type 2 diabetes PA Levin, W Wei, S Zhou, L Xie, O Baser Journal of Managed Care Pharmacy 20 (5), 501-512, 2014 | 46 | 2014 |
Hypoglycemia after initiation of basal insulin in patients with type 2 diabetes in the United States: implications for treatment discontinuation and healthcare costs and … MR Dalal, M Kazemi, F Ye, L Xie Advances in therapy 34, 2083-2092, 2017 | 45 | 2017 |
Real-world outcomes of initiating insulin glargine-based treatment versus premixed analog insulins among US patients with type 2 diabetes failing oral antidiabetic drugs O Baser, K Tangirala, W Wei, L Xie ClinicoEconomics and Outcomes Research, 497-505, 2013 | 44 | 2013 |
A real-world study of patients with type 2 diabetes initiating basal insulins via disposable pens L Xie, W Wei, C Pan, J Du, O Baser Advances in therapy 28, 1000-1011, 2011 | 44 | 2011 |
Treatment patterns, healthcare resource utilization and costs among schizophrenia patients treated with long-acting injectable versus oral antipsychotics A Shah, L Xie, F Kariburyo, Q Zhang, M Gore Advances in Therapy 35, 1994-2014, 2018 | 39 | 2018 |
Comparative persistence and adherence with newer anti-hyperglycemic agents to treat patients with type 2 diabetes in the United States J Cai, Y Wang, O Baser, L Xie, W Chow Journal of medical economics 19 (12), 1175-1186, 2016 | 37 | 2016 |